| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$209.4M | ROE | −60.27% |
| Net Margin | — | ROIC | −204.34% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Rocket Pharmaceuticals, with its subsidiaries, is a late-stage biotechnology company developing, manufacturing, and selling genetic therapies for rare diseases in the United States. It develops in vivo adeno-associated viral programs, including RP-A501 for Danon disease in Phase 2, RP-A601 for Plakophilin-2 arrhythmogenic cardiomyopathy in Phase 1, and a program targeting BAG3 dilated cardiomyopathy. These programs address multi-organ and inheritable cardiac disorders.
| Market Cap | $342.9M | Trading Days | 2872 |
| 52W High | 5.45 |
| 52W Low | 2.53 |
| % Off High | −42.39% |
| YTD | −10.54% | 1Y | 0.96% |
| 3Y | −82.58% | 5Y | −91.93% |
| 10Y | −91.73% | Since incept. (ann.) | −16.29% |
| Ann. Volatility (1Y) | 76.47% | Ann. Volatility (3Y) | 81.02% |
| Sharpe (1Y) | 0.38 | Sharpe (3Y) | −0.24 |
| Max Drawdown (1Y) | −49.81% | Max Drawdown (3Y) | −92.71% |
| Beta (3Y, vs SPY) | 0.40 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ABEO | ABEONA THERAPEUTICS INC. | $343.1M | 6.0 |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $328.9M | — |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M | — |
| CATX | Perspective Therapeutics, Inc. | $327.3M | — |
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
| ORGO | Organogenesis Holdings Inc. | $325.5M | 16.9 |
| NATR | NATURES SUNSHINE PRODUCTS INC | $364.7M | 19.6 |
| ENTA | ENANTA PHARMACEUTICALS INC |
| $366.7M |
| — |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
